Financhill
Sell
40

STRR Quote, Financials, Valuation and Earnings

Last price:
$2.19
Seasonality move :
9.1%
Day range:
$2.13 - $2.43
52-week range:
$2.06 - $5.44
Dividend yield:
0%
P/E ratio:
0.70x
P/S ratio:
0.14x
P/B ratio:
0.19x
Volume:
70.7K
Avg. volume:
14K
1-year change:
-58.87%
Market cap:
$7M
Revenue:
$45.8M
EPS (TTM):
-$3.08

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
STRR
Star Equity Holdings
$13.2M -$0.32 21.89% -605.27% --
CTSO
CytoSorbents
$10.2M -$0.06 28.63% -41.38% --
DCTH
Delcath Systems
$10.5M -$0.19 2204.21% -93.94% --
EXAS
Exact Sciences
$717M -$0.10 8.59% -18.18% $71.86
ILMN
Illumina
$1.1B $0.88 -4.48% 430.2% $148.36
PGNY
Progyny
$297.4M $0.37 2.66% 183.52% $30.22
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
STRR
Star Equity Holdings
$2.18 -- $7M 0.70x $0.00 0% 0.14x
CTSO
CytoSorbents
$0.90 -- $49.5M -- $0.00 0% 1.40x
DCTH
Delcath Systems
$11.97 -- $382.7M -- $0.00 0% 14.35x
EXAS
Exact Sciences
$57.48 $71.86 $10.6B -- $0.00 0% 3.91x
ILMN
Illumina
$134.96 $148.36 $21.4B -- $0.00 0% 4.89x
PGNY
Progyny
$14.71 $30.22 $1.3B 25.36x $0.00 0% 1.27x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
STRR
Star Equity Holdings
15.99% -0.852 31.89% 1.35x
CTSO
CytoSorbents
51.51% 0.791 16.8% 1.46x
DCTH
Delcath Systems
18.92% 0.853 0.79% 0.97x
EXAS
Exact Sciences
44.45% -0.061 20.38% 1.78x
ILMN
Illumina
48.34% 0.395 9.65% 1.68x
PGNY
Progyny
-- 1.563 -- 2.48x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
STRR
Star Equity Holdings
$2.8M -$5.3M -9.23% -10.13% -38.95% $420K
CTSO
CytoSorbents
$4.5M -$4.4M -70.49% -103.21% -20.27% -$2.8M
DCTH
Delcath Systems
$9.6M -$1.3M -167.55% -251.36% -11.24% -$3.9M
EXAS
Exact Sciences
$512.6M -$20.8M -3.82% -6.77% -4.11% $112.6M
ILMN
Illumina
$745M $253M -26.73% -37.83% 70% $284M
PGNY
Progyny
$59.2M $12.5M 11.31% 11.31% 4.35% $42.7M

Star Equity Holdings vs. Competitors

  • Which has Higher Returns STRR or CTSO?

    CytoSorbents has a net margin of -14.42% compared to Star Equity Holdings's net margin of -27.1%. Star Equity Holdings's return on equity of -10.13% beat CytoSorbents's return on equity of -103.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    STRR
    Star Equity Holdings
    20.62% -$0.78 $69.5M
    CTSO
    CytoSorbents
    52.3% -$0.04 $26.8M
  • What do Analysts Say About STRR or CTSO?

    Star Equity Holdings has a consensus price target of --, signalling upside risk potential of 358.72%. On the other hand CytoSorbents has an analysts' consensus of -- which suggests that it could grow by 455.56%. Given that CytoSorbents has higher upside potential than Star Equity Holdings, analysts believe CytoSorbents is more attractive than Star Equity Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    STRR
    Star Equity Holdings
    0 0 0
    CTSO
    CytoSorbents
    0 0 0
  • Is STRR or CTSO More Risky?

    Star Equity Holdings has a beta of 0.080, which suggesting that the stock is 91.951% less volatile than S&P 500. In comparison CytoSorbents has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.192%.

  • Which is a Better Dividend Stock STRR or CTSO?

    Star Equity Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Star Equity Holdings pays 7.62% of its earnings as a dividend. CytoSorbents pays out -- of its earnings as a dividend. Star Equity Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios STRR or CTSO?

    Star Equity Holdings quarterly revenues are $13.7M, which are larger than CytoSorbents quarterly revenues of $8.6M. Star Equity Holdings's net income of -$2M is higher than CytoSorbents's net income of -$2.3M. Notably, Star Equity Holdings's price-to-earnings ratio is 0.70x while CytoSorbents's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Star Equity Holdings is 0.14x versus 1.40x for CytoSorbents. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STRR
    Star Equity Holdings
    0.14x 0.70x $13.7M -$2M
    CTSO
    CytoSorbents
    1.40x -- $8.6M -$2.3M
  • Which has Higher Returns STRR or DCTH?

    Delcath Systems has a net margin of -14.42% compared to Star Equity Holdings's net margin of 16.64%. Star Equity Holdings's return on equity of -10.13% beat Delcath Systems's return on equity of -251.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    STRR
    Star Equity Holdings
    20.62% -$0.78 $69.5M
    DCTH
    Delcath Systems
    85.36% $0.06 $10.6M
  • What do Analysts Say About STRR or DCTH?

    Star Equity Holdings has a consensus price target of --, signalling upside risk potential of 358.72%. On the other hand Delcath Systems has an analysts' consensus of -- which suggests that it could grow by 78.22%. Given that Star Equity Holdings has higher upside potential than Delcath Systems, analysts believe Star Equity Holdings is more attractive than Delcath Systems.

    Company Buy Ratings Hold Ratings Sell Ratings
    STRR
    Star Equity Holdings
    0 0 0
    DCTH
    Delcath Systems
    0 0 0
  • Is STRR or DCTH More Risky?

    Star Equity Holdings has a beta of 0.080, which suggesting that the stock is 91.951% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.882%.

  • Which is a Better Dividend Stock STRR or DCTH?

    Star Equity Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Star Equity Holdings pays 7.62% of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend. Star Equity Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios STRR or DCTH?

    Star Equity Holdings quarterly revenues are $13.7M, which are larger than Delcath Systems quarterly revenues of $11.2M. Star Equity Holdings's net income of -$2M is lower than Delcath Systems's net income of $1.9M. Notably, Star Equity Holdings's price-to-earnings ratio is 0.70x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Star Equity Holdings is 0.14x versus 14.35x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STRR
    Star Equity Holdings
    0.14x 0.70x $13.7M -$2M
    DCTH
    Delcath Systems
    14.35x -- $11.2M $1.9M
  • Which has Higher Returns STRR or EXAS?

    Exact Sciences has a net margin of -14.42% compared to Star Equity Holdings's net margin of -5.4%. Star Equity Holdings's return on equity of -10.13% beat Exact Sciences's return on equity of -6.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    STRR
    Star Equity Holdings
    20.62% -$0.78 $69.5M
    EXAS
    Exact Sciences
    72.33% -$0.21 $5.8B
  • What do Analysts Say About STRR or EXAS?

    Star Equity Holdings has a consensus price target of --, signalling upside risk potential of 358.72%. On the other hand Exact Sciences has an analysts' consensus of $71.86 which suggests that it could grow by 25.01%. Given that Star Equity Holdings has higher upside potential than Exact Sciences, analysts believe Star Equity Holdings is more attractive than Exact Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    STRR
    Star Equity Holdings
    0 0 0
    EXAS
    Exact Sciences
    17 3 0
  • Is STRR or EXAS More Risky?

    Star Equity Holdings has a beta of 0.080, which suggesting that the stock is 91.951% less volatile than S&P 500. In comparison Exact Sciences has a beta of 1.237, suggesting its more volatile than the S&P 500 by 23.719%.

  • Which is a Better Dividend Stock STRR or EXAS?

    Star Equity Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Star Equity Holdings pays 7.62% of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend. Star Equity Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios STRR or EXAS?

    Star Equity Holdings quarterly revenues are $13.7M, which are smaller than Exact Sciences quarterly revenues of $708.7M. Star Equity Holdings's net income of -$2M is higher than Exact Sciences's net income of -$38.2M. Notably, Star Equity Holdings's price-to-earnings ratio is 0.70x while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Star Equity Holdings is 0.14x versus 3.91x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STRR
    Star Equity Holdings
    0.14x 0.70x $13.7M -$2M
    EXAS
    Exact Sciences
    3.91x -- $708.7M -$38.2M
  • Which has Higher Returns STRR or ILMN?

    Illumina has a net margin of -14.42% compared to Star Equity Holdings's net margin of 65.28%. Star Equity Holdings's return on equity of -10.13% beat Illumina's return on equity of -37.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    STRR
    Star Equity Holdings
    20.62% -$0.78 $69.5M
    ILMN
    Illumina
    68.98% $4.42 $4.1B
  • What do Analysts Say About STRR or ILMN?

    Star Equity Holdings has a consensus price target of --, signalling upside risk potential of 358.72%. On the other hand Illumina has an analysts' consensus of $148.36 which suggests that it could grow by 21.16%. Given that Star Equity Holdings has higher upside potential than Illumina, analysts believe Star Equity Holdings is more attractive than Illumina.

    Company Buy Ratings Hold Ratings Sell Ratings
    STRR
    Star Equity Holdings
    0 0 0
    ILMN
    Illumina
    9 10 0
  • Is STRR or ILMN More Risky?

    Star Equity Holdings has a beta of 0.080, which suggesting that the stock is 91.951% less volatile than S&P 500. In comparison Illumina has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.544%.

  • Which is a Better Dividend Stock STRR or ILMN?

    Star Equity Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Star Equity Holdings pays 7.62% of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend. Star Equity Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios STRR or ILMN?

    Star Equity Holdings quarterly revenues are $13.7M, which are smaller than Illumina quarterly revenues of $1.1B. Star Equity Holdings's net income of -$2M is lower than Illumina's net income of $705M. Notably, Star Equity Holdings's price-to-earnings ratio is 0.70x while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Star Equity Holdings is 0.14x versus 4.89x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STRR
    Star Equity Holdings
    0.14x 0.70x $13.7M -$2M
    ILMN
    Illumina
    4.89x -- $1.1B $705M
  • Which has Higher Returns STRR or PGNY?

    Progyny has a net margin of -14.42% compared to Star Equity Holdings's net margin of 3.64%. Star Equity Holdings's return on equity of -10.13% beat Progyny's return on equity of 11.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    STRR
    Star Equity Holdings
    20.62% -$0.78 $69.5M
    PGNY
    Progyny
    20.67% $0.11 $434.9M
  • What do Analysts Say About STRR or PGNY?

    Star Equity Holdings has a consensus price target of --, signalling upside risk potential of 358.72%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 28.19%. Given that Star Equity Holdings has higher upside potential than Progyny, analysts believe Star Equity Holdings is more attractive than Progyny.

    Company Buy Ratings Hold Ratings Sell Ratings
    STRR
    Star Equity Holdings
    0 0 0
    PGNY
    Progyny
    4 4 0
  • Is STRR or PGNY More Risky?

    Star Equity Holdings has a beta of 0.080, which suggesting that the stock is 91.951% less volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

  • Which is a Better Dividend Stock STRR or PGNY?

    Star Equity Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Star Equity Holdings pays 7.62% of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend. Star Equity Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios STRR or PGNY?

    Star Equity Holdings quarterly revenues are $13.7M, which are smaller than Progyny quarterly revenues of $286.6M. Star Equity Holdings's net income of -$2M is lower than Progyny's net income of $10.4M. Notably, Star Equity Holdings's price-to-earnings ratio is 0.70x while Progyny's PE ratio is 25.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Star Equity Holdings is 0.14x versus 1.27x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STRR
    Star Equity Holdings
    0.14x 0.70x $13.7M -$2M
    PGNY
    Progyny
    1.27x 25.36x $286.6M $10.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is AMD Stock an All-Time Buy?
Is AMD Stock an All-Time Buy?

Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…

How High Will Airbnb Stock Go?
How High Will Airbnb Stock Go?

Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 43x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
57
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
64
ARQQ alert for Dec 27

Arqit Quantum [ARQQ] is down 3.22% over the past day.

Buy
64
QMCO alert for Dec 27

Quantum [QMCO] is up 4.72% over the past day.

Buy
65
ALGS alert for Dec 27

Aligos Therapeutics [ALGS] is down 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock